Merck: FDA panel recommends expanded use of Keytruda
(CercleFinance.com) - Positive news came from Merck yesterday, as a Food and Drug Administration advisory committee recommendeded approval of its Keytruda blockbuster drug to patients with bladder cancer.
The FDA's oncologic drugs advisory committee voted 9-4 in favor of recommending Merck's immunotherapy for the treatment of certain patients with high-risk, non-muscle invasive bladder cancer.
Keytruda - which works by boosting the body's immune system's ability to help detect and fight tumor cells - is currently being studied in over 1,000 trials across a wide variety of cancers.
Separately, Merck said that it has completed its acquisition of Vaki, a maker of fish farming and wild fish conservation monitoring equipment, to strenghten its fish health and welfare business.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
The FDA's oncologic drugs advisory committee voted 9-4 in favor of recommending Merck's immunotherapy for the treatment of certain patients with high-risk, non-muscle invasive bladder cancer.
Keytruda - which works by boosting the body's immune system's ability to help detect and fight tumor cells - is currently being studied in over 1,000 trials across a wide variety of cancers.
Separately, Merck said that it has completed its acquisition of Vaki, a maker of fish farming and wild fish conservation monitoring equipment, to strenghten its fish health and welfare business.
Copyright (c) 2019 CercleFinance.com. All rights reserved.